Selected Publications

DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA.: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. Nat Med Sep 2025.

Jacob B. Reibel, Christopher A. D’Avella, Igor Makhlin2 , Mengru Wang, Maneet Kaur , Yunzhi Qian, Rebecca L. Maniago, Ivy P. Altomare, Lawrence N. Shulman: Guideline concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. ASCO Quality Care Symposium 2025.

Igor Makhlin: Dissecting Biologic Risk Using Genomic Assays - Implications for Extended Endocrine Therapy and Beyond. JAMA Network Open - In Press. Lawrence Shulman (eds.). JAMA November 27 2024 Notes: In Press - publication date 11/27/24.

Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A.: Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights. JCO Oncol Pract Aug 2024.

Makhlin I, Demissei BG, D'Agostino R, Hundley WG, Baleanu-Gogonea C, Wilcox NS, Chen A, Smith AM, O'Connell NS, Januzzi JL, Lesser GJ, Scherrer-Crosbie M, Ibáñez B, Tang WHW, Ky B.: Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial. Clin Cancer Res 30: 2370-2376, Jun 2024.

Debashish Tripathy, Kashif Ali, Laila Agrawal, Sami M. Ali, Sibel Blau, Margaret Block, Michael A. Danso, Denise Yardley, Jay Andersen, Adrienne Gropper Waks, Priya Jayachandran, Igor Makhlin, Petros Nikolinakos, Richard Zuniga, Joyce O'Shaughnessy, Sandra Aung, Janice M. Lu, Kevin Kalinsky, William John Gradishar, Hope S. Rugo: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). Journal of Clinical Oncology 42(16_suppl), May 2024.

A. DeMichele A.S. Clark L. Bayne K. Rohn I. Nivar P. Wileyto L. Berry S. DeLuca J. Savage I. Makhlin T.C. Pan J. Graves G. Belka J. Wang N. Shih D. Berry A. Nayak M. Feldman L. Chodosh: 244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”). ESMO Abstract. Annals of Oncology, 34: S281, October 2023 Notes: Abstract at ESMO 2023 - Was presented as a mini-oral by Dr. DeMichele

Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S, Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A, Gong Y.: Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. J Am Heart Assoc 12: e029361, Jun 2023.

Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA.: PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Breast Cancer Res 25(1): 1, Jan 3 2023.

Kaufmann T, Chang P, Rosenberg SM, Frank E, Hobbs B, Bayne LJ, Nivar I, Goodspeed BL, Rohn KM, Kugler EM, Fox K, Domchek SM, Bradbury A, Shah PD, Knollman h, Jankowitz RC, Makhlin I, Clark AS, Chodosh LA, DeMichele A, Goodfellow KE. : P5-08-01: Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors. San Antonio Breast Cancer Symposium 2022, San Antonio, TX. Dec 2022 Notes: "Poster Presentation"